Disease relevance of AIDS-007775

• In vitro activities of meropenem, PD 127391, PD 131628, ceftazidime, chloramphenicol, co-trimoxazole, and ciprofloxacin against Pseudomonas cepacia [1].
• The susceptibility of Neisseria gonorrhoeae to PD 131628 and grepafloxacin (OPC 17116) was evaluated by agar dilution and disc diffusion methods [2].
• PD 131628 was two to eight times more active against Gram-positive species and against Xanthomonas maltophilia [3].
• PD 131628 was very active against Neisseria spp., Haemophilus influenzae and Moraxella catarrhalis, with MIC90s ranging from 0.004 to 0.008 mg/L [4].
• The new fluoroquinolones clinafloxacin, CI-990 (PD 131112/PD 131628), sparfloxacin, and PD 138312 were bactericidal against Staphylococcus aureus with MICs > or = 4-fold lower than ciprofloxacin values [5].

High impact information on AIDS-007775

• In these in vitro comparisons with ciprofloxacin, PD 131628 is more active against gram-positive organisms, approximately equivalent against gram-negative organisms, and, like most other quinolones, relatively inactive against gram-negative anaerobes [6].
• In vitro antibacterial activities of PD 131628, a new 1,8-naphthyridine anti-infective agent [6].
• Quality control studies with N. gonorrhoeae ATCC 49226 suggested that agar dilution MIC limits were 0.002-0.008 mg/L and 0.004-0.03 mg/L for PD 131628 and grepafloxacin, respectively [2].
• The in-vitro activities of two new fluoroquinolones, clinafloxacin (CI-960, PD 127391, AM-1091) and PD 131628 (the active component of the pro-drug CI-990, PD 131112) and nine other antibiotics were tested against 107 clinical isolates of Pseudomonas aeruginosa, 12 isolates of Xanthomonas maltophilia, and 19 isolates of other Pseudomonas spp [7].
• The protein binding of PD 131628 was at most 25% across a broad range of concentrations [4].

Chemical compound and disease context of AIDS-007775

• In-vitro susceptibilities of Pseudomonas aeruginosa and Pseudomonas spp. to the new fluoroquinolones clinafloxacin and PD 131628 and nine other antimicrobial agents [7].
• Against E. coli, the intraphagocytic activity of clinafloxacin (0.001-0.005 microgram/ml and above) was superior to that of PD 131628 or ciprofloxacin, which were approximately equipotent [8].

Anatomical context of AIDS-007775

• An in vitro investigation of the bioactivities of ciprofloxacin and the new fluoroquinolone agents clinafloxacin (CI-960) and PD 131628 against Mycobacterium tuberculosis in human macrophages [9].

References